Drugs / HP-002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07658352 | Jun 2026 → Jun 2029 expected | B-cell non-Hodgkin lymphoma | Shanghai Helioson Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HP-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07658352 ↗ |